Titlebook: Diagnosis and Management of Pulmonary Hypertension; James R. Klinger,Robert P. Frantz Book 2015 Springer Science+Business Media New York 2

Cupidity

High Performance Fuzzy Processorsvascular resistance, cardiac output, or combinations thereof. When the mechanism of PH is related to an elevation in vascular resistance, the term pulmonary . hypertension is used, and may occur in the presence or absence of certain associated conditions. Identification of this subset is important a

傻瓜

他去就結(jié)束

pRAM: The Probabilistic RAM Neural Processor ultimately right heart catheterization. Proper interpretation of the considerable data that is generated by this process requires a firm working knowledge of the pulmonary circulation and right ventricle along with major factors that can affect pulmonary vascular tone and cardiac output. This chapt

印第安人

somnambulism

Siddharth Garg,Jeyavijayan (JV) Rajendranspecific, time-honored treatments in an effort to help these unfortunate patients. While the role of these therapies has not been rigorously studied they are still commonly used as adjuncts to PAH-specific therapies. This chapter outlines the logic and rationale behind the use of digoxin therapy, an

頂點(diǎn)

Siddharth Garg,Jeyavijayan (JV) Rajendranr a long time, the only treatment specifically approved for this devastating disease. As new therapies have emerged for PAH in recent years, the class of prostacyclins has also evolved and several formulations of different prostacyclin analogs, using various routes of delivery, have been tested and

UNT

是貪求

Respond

Yildiran Yilmaz,Viet-Hoa Do,Basel Halakd most patients will experience progression of their disease despite treatment. Presently available medications target four different cellular signaling pathways that have been implicated in the pathogenesis of PAH. It is unclear to what extent each pathway contributes to the progression of pulmonar

Flatter

Anomaly Detection in an Embedded System to treat the disease, no cure is presently available. New treatments for PAH that are able to reverse the abnormal pulmonary vascular remodeling that is responsible for much of this disease are badly needed. To accomplish this goal, novel therapies that target many of the dysfunctional pathways tha